Form 8-K - Current report:
SEC Accession No. 0001213900-25-040727
Filing Date
2025-05-07
Accepted
2025-05-07 17:20:59
Documents
15
Period of Report
2025-05-07
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0241210-8k_inmune.htm   iXBRL 8-K 28315
2 LETTER FROM MARCUM LLP DATED MAY 7, 2025 ea024121001ex16-1_inmune.htm EX-16.1 1754
3 GRAPHIC ex16-1_001.jpg GRAPHIC 3877
  Complete submission text file 0001213900-25-040727.txt   210503

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20250507.xsd EX-101.SCH 3017
5 XBRL LABEL FILE inmb-20250507_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE inmb-20250507_pre.xml EX-101.PRE 22360
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0241210-8k_inmune_htm.xml XML 3679
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 25922802
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)